Table 2.
Treatment at the time of enrollment
| Treatment at enrollment | Ivabradine group (n=37; 33.33%), n (%) | Nonivabradine group (n=74; 66.67%), n (%) |
|---|---|---|
| Ivabradine dose (mg BID) | ||
| 2.5 | 15 (40.54) | |
| 5 | 16 (43.24) | |
| 7.5 | 6 (16.22) | |
| B-blocker | 33 (89.19) | 73 (98.65) |
| ACE inhibitor | 23 (62.16) | 58 (78.38) |
| ARB | 9 (24.32) | 13 (17.57) |
| Non | 5 (13.51) | 3 (4.05) |
| Diuretics (excluding MRAs) | 33 (89.19) | 69 (93.24) |
| MRAs | 21 (56.76) | 37 (50.00) |
| Glycosides | 4 (10.81) | 8 (10.81) |
Indicates mean and SD. Categorical variables represented by number of patients and percentage. ACE: Angiotensin-converting enzyme, ARB: Angiotensin receptor blocker, MRAs: Mineralocorticoid receptor antagonist, SD: Standard deviation